118 related articles for article (PubMed ID: 17497745)
1. Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients.
Aref S; Osman E; Mansy S; Omer N; Azmy E; Goda T; El-Sherbiny M
Hematol Oncol; 2007 Sep; 25(3):121-6. PubMed ID: 17497745
[TBL] [Abstract][Full Text] [Related]
2. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E; Benatti C; Malcovati L; Della Porta MG; Gallì A; Bonetti E; Rosti V; Cazzola M; Invernizzi R
Eur J Haematol; 2008 Mar; 80(3):216-26. PubMed ID: 18081721
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
4. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
5. Endostatin serum level in acute myeloid leukemia.
Wrobel T; Mazur G; Kapelko K; Kuliczkowski K
Neoplasma; 2005; 52(2):182-4. PubMed ID: 15800718
[TBL] [Abstract][Full Text] [Related]
6. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
Verstovsek S; Manshouri T; Smith FO; Giles FJ; Cortes J; Estey E; Kantarjian H; Keating M; Jeha S; Albitar M
Cancer; 2003 May; 97(9):2212-7. PubMed ID: 12712473
[TBL] [Abstract][Full Text] [Related]
7. Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML.
Kuittinen O; Savolainen ER; Koistinen P; Turpeenniemi-Hujanen T
Anticancer Res; 1999; 19(5C):4395-400. PubMed ID: 10650782
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
[TBL] [Abstract][Full Text] [Related]
9. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome.
Novotny JR; Müller-Beissenhirtz H; Herget-Rosenthal S; Kribben A; Dührsen U
Eur J Haematol; 2005 Jun; 74(6):501-10. PubMed ID: 15876254
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum endostatin levels are associated with favorable outcome in acute myeloid leukemia.
Aref S; El-Sherbiny M; Azmy E; Goda T; Selim T; El-Refaie M; Twafik E
Hematology; 2008 Apr; 13(2):95-100. PubMed ID: 18616876
[TBL] [Abstract][Full Text] [Related]
11. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
Appelbaum FR; Kopecky KJ; Tallman MS; Slovak ML; Gundacker HM; Kim HT; Dewald GW; Kantarjian HM; Pierce SR; Estey EH
Br J Haematol; 2006 Oct; 135(2):165-73. PubMed ID: 16939487
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
Sperr WR; Mitterbauer M; Mitterbauer G; Kundi M; Jäger U; Lechner K; Valent P
Clin Cancer Res; 2005 Sep; 11(18):6536-43. PubMed ID: 16166430
[TBL] [Abstract][Full Text] [Related]
13. Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
Vial JP; Tabrizi R; Pigneux A; Lacombe F; Praloran V; Belloc F
Cytometry B Clin Cytom; 2006 May; 70(3):115-23. PubMed ID: 16572429
[TBL] [Abstract][Full Text] [Related]
14. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
[TBL] [Abstract][Full Text] [Related]
15. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
Vasala K; Turpeenniemi-Hujanen T
Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
[TBL] [Abstract][Full Text] [Related]
16. Significant elevation of plasma matrix metalloproteinase-9 level and its ratio to matrix metalloproteinase-2 in patients with pelvic inflammatory disease.
Wang PH; Tsai HT; Tee YT; Lin LY; Yang SF; Hsieh YS
Fertil Steril; 2009 Nov; 92(5):1679-84. PubMed ID: 18937938
[TBL] [Abstract][Full Text] [Related]
17. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
18. Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia.
Mazur G; Wróbel T; Butrym A; Kapelko-Słowik K; Poreba R; Kuliczkowski K
Neoplasma; 2007; 54(4):285-9. PubMed ID: 17822317
[TBL] [Abstract][Full Text] [Related]
19. Circulating endothelial cells in patients with acute myeloid leukemia.
Wierzbowska A; Robak T; Krawczyńska A; Wrzesień-Kuś A; Pluta A; Cebula B; Smolewski P
Eur J Haematol; 2005 Dec; 75(6):492-7. PubMed ID: 16313261
[TBL] [Abstract][Full Text] [Related]
20. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
